AU Patent

AU2020413580B2 — Complex formulation comprising sitagliptin and dapagliflozin, and preparation method therefor

Assigned to Hanmi Pharmaceutical Co Ltd · Expires 2026-01-29 · 0y expired

What this patent protects

Provided are a complex formulation comprising sitagliptin and dapagliflozin, and a preparation method therefor.

USPTO Abstract

Provided are a complex formulation comprising sitagliptin and dapagliflozin, and a preparation method therefor.

Drugs covered by this patent

metformin-hydrochloride (METFORMIN HYDROCHLORIDE)

Patent Metadata

Patent number: AU2020413580B2
Jurisdiction: AU
Classification: —
Expires: 2026-01-29
Drug substance claim: No
Drug product claim: No
Assignee: Hanmi Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.